Table 5.
Nonimmunologic profile.
| Factor | Tacrolimus (FK 506) | Cyclosporin A | ||
|---|---|---|---|---|
| Nephrotoxicity | ++a | ++ | ||
| Neurotoxicity | + | + | ||
| Diabetogenicity | + | + | ||
| Growth effects | ||||
| Hirsutism | 0 | +++ | ||
| Gingival hyperplasia | 0 | ++ | ||
| Facial brutalization | 0 | + | ||
| Hepatotrophic effects | ++++ | +++ | ||
| Gynecomastia | 0 | + | ||
| Other metabolic effects | ||||
| Cholesterol increase | 0b | ++ | ||
| Uric acid increase | +? | ++ | ||
Reprinted from Starzl et al. [214], copyright 1991, with permission from Elsevier Science.
+: best; ++++: worst (all dose-related).
a
Less hypertension.
b
Despite this observation in humans [161] Van Thiel observed an increase in cholesterol synthesis and serum concentration in rats (personal communication, August 1, 1990).